A
Ajeet Singh Bhadoria
Researcher at All India Institute of Medical Sciences
Publications - 135
Citations - 2616
Ajeet Singh Bhadoria is an academic researcher from All India Institute of Medical Sciences. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 18, co-authored 111 publications receiving 1809 citations.
Papers
More filters
Journal ArticleDOI
Childhood obesity: causes and consequences
Krushnapriya Sahoo,Bishnupriya Sahoo,Ashok Choudhury,Nighat Yaseen Sofi,Raman Kumar,Ajeet Singh Bhadoria +5 more
TL;DR: There are supporting evidence that excessive sugar intake by soft drink, increased portion size, and steady decline in physical activity have been playing major roles in the rising rates of obesity all around the world.
Journal ArticleDOI
Combination of Granulocyte Colony-Stimulating Factor and Erythropoietin Improves Outcomes of Patients With Decompensated Cirrhosis
Chandan Kumar Kedarisetty,Lovkesh Anand,Ankit Bhardwaj,Ajeet Singh Bhadoria,Guresh Kumar,Ashish Kumar Vyas,Paul David,Nirupama Trehanpati,Archana Rastogi,Chhagan Bihari,Rakhi Maiwall,Hitendra Garg,Chitranshu Vashishtha,Manoj Kumar,Vikram Bhatia,Shiv Kumar Sarin +15 more
TL;DR: In a single-center randomized trial, a significantly larger proportion of patients with decompensated cirrhosis given a combination of G-CSF and darbopoietin α survived for 12 months more than patients given only placebo.
Journal ArticleDOI
Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.
Mingjuan Tan,Ajeet Singh Bhadoria,Fuqiang Cui,Alex Tan,Judith van Holten,Philippa Easterbrook,Nathan Ford,Qin Han,Ying Lu,Marc Bulterys,Yvan Hutin +10 more
TL;DR: The proportion of people with chronic HBV infection who were eligible for antiviral treatment worldwide, based on the WHO 2015 guidelines, was estimated, with a pooled estimate of eligibility at 19%, ranging from 12% for studies in community settings to 25% in clinic settings.
Journal ArticleDOI
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial
Ankit Bhardwaj,Chandan Kumar Kedarisetty,Chitranshu Vashishtha,Ajeet Singh Bhadoria,Ankur Jindal,Guresh Kumar,Ashok Choudhary,Saggere Muralikrishna Shasthry,Rakhi Maiwall,Manoj Kumar,Vikram Bhatia,Shiv Kumar Sarin +11 more
TL;DR: Carvedilol is safe and effective in delaying the progression of small to large oesophageal varices in patients with cirrhosis and no major adverse events were observed in either group.
Journal ArticleDOI
Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial
Kapil Sharma,Sanjay Pant,S. P. Misra,Manisha Dwivedi,Alok Misra,Sushil Narang,Reshu Tewari,Ajeet Singh Bhadoria +7 more
TL;DR: Rifaximin, LOLA, and probiotics are better than giving placebo in patients with MHE as compared with placebo group, and CFF scores and improvement in psychometric tests after treatment were significantly higher.